Clinical trial
Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
NCT00153907 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00153907 |
|---|---|
| Title | Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer |
| Official title | A Phase I Study of Oral Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Massachusetts General Hospital |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Navelbine, Capecitabine |
| Enrollment | 40 |
| Start date | Mar 1, 2002 |
| Primary completion | Sep 1, 2011 |
| Completion | Sep 1, 2011 |
| First posted | Sep 12, 2005 |
| Last update posted | Feb 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: